NEW YORK (GenomeWeb) – Twist Bioscience announced today that it has acquired Israeli synthetic biology software company Genome Compiler.
Under the terms of the agreement, the Genome Compiler research and development center in Israel will remain open as Twist's first international site. Financial terms of the deal were not disclosed.
Twist said it plans to use Genome Compiler's technology and expertise to develop a digital products portfolio, including an e-commerce solution with gene design capabilities, which is expected to be available in the second half of 2016.
"Twist's beta program is progressing well and our first customer shipments are underway," said Twist CEO Emily Leproust in a statement. "Over the next few months we expect to scale our gene volume substantially, enabling us to offer market-leading production levels by this summer. We are delighted to bring the Genome Compiler technology, network, and expert team into the Twist Bioscience organization. They are the leader in developing software that allows design of gene sequences for synthetic and molecular biology experiments."
Leproust said Twist's e-commerce pipeline will include several digital products that will provide researchers with seamless integration of the design and building of synthetic DNA.